Background Pembrolizumab plus pemetrexed–platinum led to superior overall survival and
progression-free survival, and a higher proportion of patients with a confirmed complete or …

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum
significantly improved overall survival (OS) and progression-free survival (PFS) compared …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …

Pembrolizumab plus pemetrexed‐platinum significantly improved overall survival (OS) and
progression‐free survival (PFS) with manageable safety compared with placebo plus …

Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …

Abstract Introduction Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and
safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line …

Background Limited evidence exists to show that adding a third agent to platinum-doublet
chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

Background First-line pembrolizumab monotherapy improves overall and progression-free
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …